Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods

Shazad Mushtaq; Marina Warner; Alan P Johnson; David M Livermore

doi:10.1093/jac/dkh401

Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods

Shazad Mushtaq, Marina Warner, Alan P Johnson, David M Livermore

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

Abstract

Dalbavancin is a long-half-life (9-12 days) glycopeptide, now in Phase 3 development. Its pharmacokinetics may facilitate home intravenous therapy, early discharge and long prophylaxis.

Original language	English
Pages (from-to)	617-20
Number of pages	4
Journal	Journal of Antimicrobial Chemotherapy
Volume	54
Issue number	3
DOIs	https://doi.org/10.1093/jac/dkh401
Publication status	Published - Sept 2004

Keywords

Anti-Bacterial Agents
Culture Media
Drug Resistance, Multiple, Bacterial
Glycopeptides
Microbial Sensitivity Tests
Staphylococcus
Streptococcus
Teicoplanin

Access to Document

10.1093/jac/dkh401

Cite this

@article{07c30984331c4b9cbffddb33f05d066a,

title = "Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods",

abstract = "Dalbavancin is a long-half-life (9-12 days) glycopeptide, now in Phase 3 development. Its pharmacokinetics may facilitate home intravenous therapy, early discharge and long prophylaxis.",

keywords = "Anti-Bacterial Agents, Culture Media, Drug Resistance, Multiple, Bacterial, Glycopeptides, Microbial Sensitivity Tests, Staphylococcus, Streptococcus, Teicoplanin",

author = "Shazad Mushtaq and Marina Warner and Johnson, {Alan P} and Livermore, {David M}",

year = "2004",

month = sep,

doi = "10.1093/jac/dkh401",

language = "English",

volume = "54",

pages = "617--20",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods

AU - Mushtaq, Shazad

AU - Warner, Marina

AU - Johnson, Alan P

AU - Livermore, David M

PY - 2004/9

Y1 - 2004/9

N2 - Dalbavancin is a long-half-life (9-12 days) glycopeptide, now in Phase 3 development. Its pharmacokinetics may facilitate home intravenous therapy, early discharge and long prophylaxis.

AB - Dalbavancin is a long-half-life (9-12 days) glycopeptide, now in Phase 3 development. Its pharmacokinetics may facilitate home intravenous therapy, early discharge and long prophylaxis.

KW - Anti-Bacterial Agents

KW - Culture Media

KW - Drug Resistance, Multiple, Bacterial

KW - Glycopeptides

KW - Microbial Sensitivity Tests

KW - Staphylococcus

KW - Streptococcus

KW - Teicoplanin

U2 - 10.1093/jac/dkh401

DO - 10.1093/jac/dkh401

M3 - Article

C2 - 15321983

SN - 0305-7453

VL - 54

SP - 617

EP - 620

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 3

ER -